Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.52 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988104 | 1.00 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL7762751 | 0.98 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Trifluoroacetic Acid SCHEMBL13519233 | 0.92 | OPRK1 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Benzoic Acid SCHEMBL28518694 | 0.92 | MMP2 (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Trifluoroacetic Acid SCHEMBL13519232 | 0.92 | OPRK1 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2311329 | 0.87 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL987883 | 0.87 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21010316 | 0.86 | SLC15A1 (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2684591 | 0.85 | ANPEP (0.51) | SLC7A5MMP2ANPEP | |
| Hydrochloric Acid SCHEMBL7202509 | 0.85 | L3MBTL1 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0520883-B1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1995-07-12 | — | — | EP | claimed |
| EP-0520883-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | claimed |
| EP-0001684-B1 | TETRAPEPTIDES, METHODS FOR THEIR PREPARATION AND THEIR USE IN ANALGESIC COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1981-09-02 | — | — | EP | claimed |
| EP-0001684-A2 | Tetrapeptides, methods for their preparation and their use in analgesic compositions | ELI LILLY AND COMPANY (US) | 1979-05-02 | — | — | EP | claimed |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | ORCHID PHARMA LTD. (IN) | 2021-11-23 | — | — | US | disclosed |
| US-8889712-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1409688-A2 | NUCLEIC ACID SEQUENCES ENCODING ENANTIOSELECTIVE AMIDASES | DSM IP Assets B.V. (NL) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010312-A2 | NUCLEIC ACID SEQUENCES ENCODING ENANTIOSELECTIVE AMIDASES | DSM IP ASSETS B.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
| EP-0495013-B1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORP (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0226217-B1 | Peptides with sulfate ester group | FISONS CORP (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0495013-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS. | FISONS CORP (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991008225-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0001684-B1 | TETRAPEPTIDES, METHODS FOR THEIR PREPARATION AND THEIR USE IN ANALGESIC COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1981-09-02 | — | — | EP | disclosed |
| EP-0001684-A2 | Tetrapeptides, methods for their preparation and their use in analgesic compositions | ELI LILLY AND COMPANY (US) | 1979-05-02 | — | — | EP | disclosed |
| US-4017513-A | Method for making aminoacid amides | ABBOTT LABORATORIES (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | OPRL1, TRPV1, ORAI1 | ALPI 4551/4885PKM 3734/4885PTGS1 1503/4885 |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | ALPI 207/4885PKM 275/4885PTGS1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.